KBRA Comments on Aviation ABS Exposure to Spirit Airlines
Spirit Airlines Inc. (Spirit), an ultra-low-cost carrier headquartered in Dania Beach, Florida, has experienced financial deterioration in recent years as the airline has struggled to recover from the COVID-19 pandemic, with recent headlines indicating that Spirit is preparing to file for bankruptcy protection.
Spirit is a lessee in six aviation lease asset-backed security (ABS) transactions rated by KBRA. While none of the exposures exceeds 10% of the underlying portfolio value, the transactions may be susceptible to future cash flow interruption due to further credit deterioration of the airline. Under bankruptcy protection, Spirit may elect to either reject or affirm its leases. If a lease is rejected, ABS cash flows could be negatively impacted while the related servicer attempts to re-lease or sell the aircraft. Leases may also be affirmed but restructured, resulting in lower lease rates, which would also negatively impact cash flows.
The six KBRA-rated aviation lease ABS transactions that have exposure to Spirit, based on data from the October 2024 payment date reports (apart from SLAM 2024-1, which is as of the closing date), include the following:
MAPS 2019-1 Limited with one aircraft, approximately 8.4% by value, serviced by Merx Aviation Servicing Limited
SLAM 2024-1 Limited with two aircraft, approximately 5.5% by value, serviced by SKY Leasing LLC
AASET 2022-1 Limited with two aircraft, approximately 5.4% by value, serviced by Carlyle Aviation Management Limited
KBRA is a full-service credit rating agency registered in the U.S., the EU, and the UK, and is designated to provide structured finance ratings in Canada. KBRA's ratings can be used by investors for regulatory capital purposes in multiple jurisdictions.
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...
Genmab A/S :
Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic...
Positive results from the AMPLIFY Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS)...
Studies being presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition highlight progress in preventing and treating blood cancers....